Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541414 | 0.84 | RECQL (0.61) | RECQLNOS3NOS1NOS2PRKCI | |
| SCHEMBL218290 | 0.84 | NOS3 (0.61) | CYP1A2POLBNOS3NOS1NOS2 | |
| SCHEMBL3638740 | 0.83 | KDM4E (0.56) | RECQLCYP1A2POLBNOS3NOS1 | |
| SCHEMBL5115940 | 0.83 | NOS3 (0.55) | RECQLCYP1A2POLBNOS3NOS1 | |
| SCHEMBL11563922 | 0.82 | NOS3 (0.59) | CYP1A2POLBNOS3NOS1NOS2 | |
| Dimethylamine SCHEMBL7744073 | 0.78 | NOS3 (0.55) | CYP1A2POLBNOS3NOS1NOS2 | |
| SCHEMBL2642380 | 0.78 | RECQL (0.55) | RECQLNOS3NOS1NOS2PRKCI | |
| SCHEMBL21393240 | 0.78 | RECQL (0.55) | RECQLCYP1A2POLBNOS3NOS1 | |
| SCHEMBL16775566 | 0.78 | CYP1A2 (0.47) | RECQLCYP1A2POLBNOS3NOS1 | |
| SCHEMBL1654460 | 0.78 | LOXL2 (0.55) | CYP1A2POLBNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547519-B2 | Monitoring mycobacterium oxidation of organosulfur compounds, obtaining bacterial nucleotide sequences, detecting mutation in preferential gene, monitoring reduction in oxidation of organosulfur compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-06-16 | — | — | US | claimed |
| EP-1453837-A4 | TARGETED THERAPEUTICS AND USES THEREOF | ACTIVBIOTICS INC (US) | 2007-11-07 | — | — | EP | claimed |
| US-7122525-B2 | Targeted therapeutics and uses thereof | ACTIVBIOTICS, INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-20050142602-A1 | Methods of diagnosing multidrug resistant tuberculosis | THE GOVT. U.S.A , AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-06-30 | — | — | US | claimed |
| EP-1453837-A2 | TARGETED THERAPEUTICS AND USES THEREOF | Activbiotics, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040063718-A1 | Targeted therapeutics and uses thereof | ACTIVBIOTICS PHARMA LLC | 2004-04-01 | — | — | US | claimed |
| WO-2003045319-A2 | TARGETED THERAPEUTICS AND USES THEREOF | ACTIVBIOTICS, INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030013090-A1 | Methods of diagnosing multidrug resistant tuberculosis | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE, DEPARTMENT OF THE, THE | 2003-01-16 | — | — | US | claimed |
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-1453837-A2 | TARGETED THERAPEUTICS AND USES THEREOF | Activbiotics, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |
| US-20040063718-A1 | Targeted therapeutics and uses thereof | ACTIVBIOTICS PHARMA LLC | 2004-04-01 | — | — | US | disclosed |
| WO-2003045319-A2 | TARGETED THERAPEUTICS AND USES THEREOF | ACTIVBIOTICS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030013090-A1 | Methods of diagnosing multidrug resistant tuberculosis | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE, DEPARTMENT OF THE, THE | 2003-01-16 | — | — | US | disclosed |
| WO-1999020617-A1 | ANTIINFLAMMATORY THIADIAZOLYL UREAS WHICH ACT AS LFA-1 AND MAC-1 INHIBITORS | ACTIVE BIOTECH AB (SE) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | RECQL 3135/4885CYP1A2 4827/4885POLB 2624/4885 |
| US-20040063718-A1 | Targeted therapeutics and uses thereof | CD47, RIF1, NUP205 | RECQL 1244/4885CYP1A2 3572/4885POLB 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.